首页> Bone marrow transplantation> Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.

Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.

导出 LinkOut

翻译打印收藏纠错

第一作者： P,Tsirigotis

第一单位： Second Department of Internal Medicine, ATTIKO University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

作者： P,Tsirigotis ^[1] ; I,Danylesko ^[2] ; K,Gkirkas ^[1] ; N,Shem-Tov ^[2] ; R,Yerushalmi ^[2] ; M,Stamouli ^[1] ; A,Avigdor ^[2] ; A,Spyridonidis ^[3] ; J,Gauthier ^[4] ; G,Goldstein ^[2] ; J,Apostolidis ^[5] ; M,Mohty ^[6] ; A,Shimoni ^[2] ; A,Nagler ^[2]

作者单位： Second Department of Internal Medicine, ATTIKO University Hospital, National and Kapodistrian University of Athens, Athens, Greece. ^[1] Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel. ^[2] Bone Marrow Transplantation Unit, University of Patras, Patras, Greece. ^[3] Bone Marrow Transplantation Unit, University of Lille, Lille, France. ^[4] Bone Marrow Transplantation and Hematology & Lymphoma Department, Evaggelismos General Hospital, Athens, Greece. ^[5] Department of Hematology, Hospital St Antoine, Paris, France. ^[6]